+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chlamydia Infection Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

  • PDF Icon


  • 112 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4896157
The chlamydia infection diagnostics market is expected to register a CAGR of 8.5% over the forecast period.

COVID-19 had a significant impact on market growth while it lasted. As per a report published by the Centers for Disease Control and Prevention (CDC) in April 2022, the decline in reported chlamydia was likely due to the decreased sexually transmitted diseases screening and underdiagnosis during the pandemic rather than a reduction in new infections. This also contributed to an overall decrease in the number of reported Sexually Transmitted infections in 2020 (from 2.5 million reported cases in 2019 to 2.4 million in 2020). According to the WHO, in 2022, it was stated that during the COVID-19 pandemic, many countries had reported low coverage for preventive testing and treatments related to sexually transmitted infections. Hence this has led to a resurgence of STIs and the emergence of non-classical STIs globally. This will elevate the market's growth over the forecast.

The chlamydia infection diagnostics market is growing due to the increasing prevalence rates of chlamydia and the growing demand for rapid testing. Owing to the rising prevalence of chlamydia and the significant shift from conventional technologies to molecular diagnostics, the market studied is growing rapidly. For instance, according to the CDC in 2021, a total of 1,628,379 cases of chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States that year. This case count corresponds to a rate of 552.8 cases per 100,000 population, an increase of 2.8% compared with the past years. The growing rates of this disease are expected to increase the diagnostics and also the need for developing more advanced tests, which is expected to increase the growth of the market during the forecast period.

Additionally, government initiatives are expected to drive the growth of the studied market. For Instance, in June 2021, the government of the United Kingdom mentioned that the National Chlamydia Screening Programme (NCSP) will focus testing on women, who are at the highest risk of serious consequences from the infection. The program aims to provide treatment more rapidly and expand testing in community settings for sexually active women aged under 25 years. Such initiatives by various governments in reducing the burden of diseases are increasing market growth. However, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.

Chlamydia Infection Diagnostics Market Trends

Nucleic Acid Amplification Test (NAAT) Based Tests Dominates the Chlamydia Infection Diagnostics Market

The Nucleic Acid Amplification Test (NAAT) is found to be the most recommended method. It is a molecular test that detects DNA, the genetic material of chlamydia trachomatis. The NAAT is thus used to detect chlamydia trachomatis RNA or DNA in biological samples to diagnose and monitor the chlamydia infection. The NAAT method is usually more sensitive and specific than the other chlamydia tests. It can be performed on a vaginal swab taken from women and urine from both men and women. Thus, it eliminates the requirement for a pelvic exam in women.

The increasing product approvals are expected to drive the growth of the studied segment. For instance, in March 2022, the United States Food and Drug Administration (FDA) announced that it would allow the use of the Binx Health IO CT/N assay at point-of-care settings in physician offices, community-based clinics, urgent care settings, and other end users. Product approvals increase the prominence of the market within a population as individuals become more aware and purchase various products for the diagnosis of chlamydia infection.

The high number of chlamydia infections will increase the need for NAAT testing, which will elevate the growth of the chlamydia infection. According to the WHO, in 2022, chlamydia affects about 129 million people globally.

North America is Expected to Dominate the Chlamydia Infection Diagnostics Market Over the Forecast Period

North America is found to hold a leading position in the chlamydia infection diagnostics market during the forecast period due to the high prevalence of chlamydia infection among individuals and new product developments by the key players. According to the CDC, in 2021, there were nearly 1.6 million cases of chlamydia reported in the United States. According to America's Health Rankings, in 2021, in New Mexico, chlamydia cases (per 100,000 population) were around 576.3.

Additionally, the increasing product approvals are expected to drive the growth of the market in this region. In August 2021, Visby Medical received the 510 (k) clearance and was granted a waiver under the clinical laboratory improvement amendments of 1988 from the United States Food and Drug Administration to market its fast PCR diagnostic test for the multiplexed detection of chlamydia. Similarly, in May 2022, Abbott received FDA clearance for its Alinity m STI assay. The Alinity m STI for Chlamydia requires one swab sample or a urine sample collected by a clinician or patient in a healthcare setting.

Chlamydia Infection Diagnostics Market Competitor Analysis

The chlamydia infection diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Some key companies in the market are Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, DiaSorin SpA, F Hoffmann-La-Roche Ltd, Hologic, and others.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence Rate of Chlamydia Infection
4.2.2 Increasing Initiatives for Chlamydia Testing and Product Innovation
4.3 Market Restraints
4.3.1 Social Stigma Associated with Patients Visiting Specialized STD Clinics
4.3.2 Huge Proportion of Patients Infected with Chlamydia in Out-of-reach Geographic Areas
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Test Type
5.1.1 Culture Tests
5.1.2 Nucleic Acid Amplification Test (NAAT)
5.1.3 Direct Fluorescent Antibody Test
5.1.4 Serology Tests
5.1.5 Other Test Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Diagnostic Centers
5.2.3 Other End Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 Bio-Rad Laboratories, Inc.
6.1.4 Danaher Corporation (Cepheid)
6.1.5 DiaSorin SpA
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Hologic, Inc.
6.1.8 Quidel Corporation
6.1.9 Laxai Pharma Ltd. (Savyon Diagnostics Ltd).
6.1.10 Trinity Biotech Plc

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (Cepheid)
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Quidel Corporation
  • Laxai Pharma Ltd. (Savyon Diagnostics Ltd).
  • Trinity Biotech Plc